Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma.
Tracy W LiuSeth T GammonPing YangWencai MaJing WangDavid Piwnica-WormsPublished in: Journal for immunotherapy of cancer (2023)
MPO contributes to ICT resistance in established melanoma. Repurposing MPO-specific inhibitors may provide a promising therapeutic strategy to enhance ICT response.
Keyphrases